Articles by Jill Wechsler - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Jill Wechsler

Issues and Opportunities Challenge Biotech Manufacturers

Demand for new vaccines and therapies in 2010 will be offset by concerns about drug prices and product safety.
Jan 1, 2010

Demand for new vaccines and therapies in 2010 will be offset by concerns about drug prices and product safety.

The Promise and Perils of Vaccines

Vaccine research and development is surging, but continues to face manufacturing and regulatory challenges.
Dec 1, 2009

Vaccine research and development is surging, but continues to face manufacturing and regulatory challenges.

Safety First in Biotech Development

Heightened attention to product safety issues is slowing the approval process for new therapies.
Nov 1, 2009

Heightened attention to product safety issues is slowing the approval process for new therapies.

FDA Leaders Stress Science and Compliance

Stiffer enforcement of quality standards aims to restore public confidence in agency actions.
Oct 1, 2009

Stiffer enforcement of quality standards aims to restore public confidence in agency actions.

Biopharmaceutical Manufacturers Seize Opportunities in the Global Health Arena

The FDA is encouraging manufacturers to invest in research and development for new vaccines and therapeutics to combat third-world diseases.
Sep 1, 2009

The FDA is encouraging manufacturers to invest in research and development for new vaccines and therapeutics to combat third-world diseases.

Health Reform Challenges Biotech Industry

Pressures to reduce healthcare spending generates proposals to spur competition, cut costs.
Aug 1, 2009

Pressures to reduce healthcare spending generates proposals to spur competition, cut costs.

Extended Risk Management Proposals Challenge Manufacturers

The FDA seeks new strategies for improving the safe use of opioids and other high-risk medicines, including erythropoiesis stimulating agents.
Jul 1, 2009

The FDA seeks new strategies for improving the safe use of opioids and other high-risk medicines, including erythropoiesis stimulating agents.

Stiffer Enforcement at the FDA

Agency officials promise swift action against violators of drug safety and quality regulations.
Jun 1, 2009

Agency officials promise swift action against violators of drug safety and quality regulations.

Comparative Effectiveness Research to Shape Biotech Studies

Authorities are pushing for CE; manufacturers prefer to focus on value.
May 1, 2009

Authorities are pushing for CE; manufacturers prefer to focus on value.

ADVERTISEMENT

ADVERTISEMENT

Click here